Role of omecamtiv mecarbil in heart failure with reduced ejection fraction (HFrEF) was published in GALACTIC- HF trial (NEJM 2021). Recently, in JACC the effect of ejection fraction on response to Omecamtiv mecarbil in patients enrolled in GALACTIC-HF trial was published.
In this presentation I have discussed both these studies together.
Omecamtiv mecarbil may find its place in newer guidelines for HFrEF.
To know more about Omecamtiv mecarbil in patients with HFrEF and both the trials published in NEJM and JACC listen to this podcast.
